Reputable Colombian medical cannabis enterprise with consistent year-round production at meaningful scale, licensed to produce, extract, and export. Backed by $15M+ in signed, multi-year contracts across regulated markets, the company is seeking a $3M strategic partner to expand capacity, fulfill contracted demand, and advance its EU-GMP roadmap targeting 2026.
Business Highlights
Export-Proven and Contracted Demand
- 10+ successful international shipments with consistent exports to regulated markets
- $15M+ contracts across Australia, Germany, the UK, Italy, Malta, and Poland
Low-Cost Production Advantage
- Estimated cost per gram of $0.10 to $0.30 versus $0.80 to $1.50 in the EU and North America
- High-margin model with 60%+ EBITDA margin potential at scale (stated)
Demonstrated Scale and Expansion Runway
- Rolling harvests up to 1,000 kgs per month (stated)
- One greenhouse is operational, and a second is planned for Q3 2025
- Licensed land capacity for 8 additional greenhouses, with stated revenue potential of about $1M to $4M+ annually per greenhouse
Genetics and Product Differentiation
- Library of 30 registered strains developed in Colombia
- Pipeline strains testing at 24% to 27% THC with ongoing optimization for cannabinoid and terpene expression
Quality and Certification Path
- Consistent quality referenced to EU Pharmacopeia and TG93 standards
- Achieved CUMCS-GACP certification and upgraded infrastructure to EU-GACP expectations
- EU-GMP roadmap targeting 2026 to enhance quality and margins
Investment Opportunity
Seeking a USD $3M strategic equity partner to execute on contracted revenue, expand production capacity, and progress toward EU-GMP certification in 2026. Strong fit for global wholesalers, EU importers, and strategic operators seeking reliable Colombian supply.
